États-Unis · Bourse & Finance · Yahoo Finance

Iambic Therapeutics (IAM) Filed An IND For IAM217

Publié par Yahoo Finance · États-Unis il y a 9 h

Iambic Therapeutics (NasdaqGS:IAM) submitted an Investigational New Drug application to the FDA for IAM217, a KIF18A inhibitor, in October 2026. IAM217 is described by the company…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Iambic Therapeutics (IAM) Filed An IND For IAM217

À lire aussi

Tether backs AIsa as strategic investor, completing seed extension round

Why hedge funds could be making a bond market shock more likely

Americans are packing town halls to stop data centers. It's working, for now

France is aflame as peaceful protests over the cost of living devolve into chaos and looting

Circle defends USDC economics as stablecoin rivals court its partners with bigger cut

New England faces record-high heating oil costs this winter

Iambic Therapeutics (IAM) Filed An IND For IAM217

Partager

À lire aussi

Tether backs AIsa as strategic investor, completing seed extension round

Why hedge funds could be making a bond market shock more likely

Americans are packing town halls to stop data centers. It's working, for now

France is aflame as peaceful protests over the cost of living devolve into chaos and looting

Circle defends USDC economics as stablecoin rivals court its partners with bigger cut

New England faces record-high heating oil costs this winter